2) This series is supported by educational grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk and is intended for healthcare providers. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/.
Now let's start with a case!
3) Case summary: 85y woman with history of GI bleeding secondary to peptic ulcer disease 3 months ago, is admitted with an NSTEMI. She is hemodynamically stable and her baseline Hb is 10 g/dl.
4) Initial angiogram:
5) Since the patient is hemodynamically stable with TIMI III flow in her epicardial coronary arteries, we do not proceed with ad hoc PCI & opt to discuss options at the heart team meeting. What would you recommend as a revascularization option in this 85 year old?
a. CABG with no antiplatelet
b. CABG with single antiplatelet
c. Complex PCI with DAPT for 1 month
d. Complex PCI with DAPT for 6 months
PLEASE VOTE
6) At the heart team meeting, we agreed to proceed with an endoscopy to determine her risk for a future bleed. It revealed a healing duodenal ulcer and no active bleeding. As such, given her age and frailty, she was deemed too high risk for CABG & complex PCI was offered.
7) Angio Post-PCI
IVUS guided PCI of the Left Main, LAD and Left Circumflex using DK Crush technique with Proximal Optimization using a 4.5 NC balloon.
#CMGsays: Join here tomorrow for the launch of a new accredited tweetorial on optimal management of diabetic and other high-risk patients with stable CAD, particularly those with previous PCI, to reduce the risk of MI or stroke. Expert faculty is the incomparable @CMichaelGibson
Join here tomorrow for the launch of a new accredited tweetorial on DAPT in patients with stable CAD+diabetes who have not (yet!) had an MI or stroke! Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @gabrielsteg. #medtwitter@academiccme#CardioTwitter
. . . This educational activity is intended for healthcare providers and is supported by grants from Abbott, AstraZeneca, Bayer, Chiesi, and NovoNordisk.
. . . and this educational activity, which is intended for healthcare providers, is supported by grants from Abbott, AstraZeneca, Bayer, Chiesi, and NovoNordisk.
Watch here tomorrow for the launch of a new accredited tweetorial on use of P2Y12 inhibitor monotherapy after PCI! Earn 0.5 CE/CME credits: physicians, nurses, pharmacists! Expert faculty @SVRaoMD. #medtwitter@academiccme#cardiotwitter
1) Welcome to a tweetorial on the use of P2Y12 inhibitor monotherapy after PCI! Accredited for 0.50 credits by @academiccme: physicians, nurses, pharmacists! I am @SVRaoMD.
2) This series is supported by educational grant funding from Abbott, AstraZeneca, Bayer, Chiesi, and NovoNordisk. Follow this thread for credit. And here is a case …
2) . . . Supported by educational grant funding from Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. Follow this thread for credit. And here is a case . . .
6/ High-degree AV block was the most powerful predictor of cardiac death. Guidelines currently don’t recommend routine ICM post-MI, unless patients have recurrent unexplained syncope with systolic impairment and don’t have a current indication for an ICD.
7/ REVISE study: 103 pts with epilepsy but likely misdiagnosed. Enrolled if 3/+transient LOC episodes in yr before enrol. ICM recorded profound bradyarrhythmia or asystole with convulsive features in 21%, who were offered pacemaker. After pacing and d/c sz meds, 60% became asx.
8/ ESUS cryptogenic stroke: a good indication for ICM, as recurrence is common and AF detection might allow treatment. Intermittent monitoring (annual 24h or quarterly 7d Holter) for AF inferior to cont ICM. ICMs shown to be a cost-effective dx'ic tool for sec prevention in ESUS.